Clinical trial NCT00834145: Effect of Normatec Pump for Relief of Leg Edema in Patients With Right Heart Failure
Official title: Effect of Normatec Pump for Relief of Leg Edema in Patients With Right Heart Failure: Short- Intermediate- and Long-Term Outcomes
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Right Heart Failure
Cor Pulmonale
Keywords: Edema
Right heart failure
Cor pulmonale
Pump
Leg compression
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2009-02-03
Enrollment: 30
Sex: ALL
Minimum age (years): 30
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Mobilization of fluid from the legs with the Normatec pump in patients with right heart failure, may empty the "reservoir" in the legs from excessive fluid, enabling fluid overload to collect there rather than in the liver or in other third spaces. Thus, we hypothesize that patients will lose weight, feel better, look better, be less prone to infections in their legs and to congestion of the liver.

Detailed description: The protocol will be divided into 2 parts:

1. The initial pumping phase will be an in-hospital study, short term study. Patients will be randomly assigned to conventional/conservative treatment or to pump therapy. Within 24 hours of admission patients assigned to pump therapy will be recruited for the study and will begin therapy according to the protocol outlined in the table below. These patients will not be given diuretics unless required to because of shortness of breath with suspected left heart failure. Individualized programs regarding pumping frequency and pump parameters will be set for each patient and will be adjusted during the first few days and maintained throughout the study unless there is a reason to modify them.

   Data on both the conventional/conservative and the pump arms of the study will be collected at similar intervals. The duration of the in-hospital period will not be extended because of the study and is expected to be 3-7 days.
2. An intermediate-term study in which the patients from the phase 1 study will be ambulatory. During this phase of the study the effect of continuous maintenance and optimization will be monitored. Patients will come to the hospital for their pumping session at which time the protocol tests will be performed. Patients that were assigned to the conventional/conservative arm in phase 1 will be examined as per protocol at 1, 2 and 3 weeks after admission but BNP levels will be repeated only after the 3rd week.
3. At 3 and 6 months after admission, the "long term" phase of the study, a systematic investigation regarding repeat hospitalizations and their causes will be carried out by telephone interview and by a review of admission data from hospital records.

Eligibility criteria: Inclusion Criteria:

* Hospitalized patients
* Adults
* Right heart failure secondary to pulmonary hypertension (cor pulmonale)
* Pronounced leg edema

Exclusion Criteria:

* Patients in sepsis
* Hemodynamically unstable
* Renal failure (creatinine \>2 mg%)
* Deep vein thrombosis
* Pregnancy
* Psychiatric/noncompliant patients
* Patients who will not sign the informed consent form

Primary outcomes:
measure: Patient weight
timeFrame: 3 and 6 months
Secondary outcomes:
measure: Leg circumference, Pulmonary pressures, Cardiac function
timeFrame: 3 and 6 months
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hille Yaffe Medical Ceter
Study officials:
References: